ClinicalTrials.gg
Not yet recruitingNCT07557615COGNI-REHABUpdated Oct 19, 2026

hCG Treatment for Rehabilitation From a TBI

An Early Phase 1 interventional study of Ovidrel and Placebo in Traumatic Brain Injury, sponsored by VA Office of Research and Development. Not yet recruiting at 1 site in United States. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by VA Office of Research and Development · Early Phase 1, Interventional, and Treatment

How we know

Updated Oct 13, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development — 8 open to participants now, 8 under way, none of them phase 3. Brain Injuries, Traumatic · VA Office of Research and Development.

Planned enrollment
28th of 46
50 · median 61
Started
2027
with 1 other
Phase 1
3 of 55
2 open now
Registered
55th of 55
by date

Among the 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development, this one is the 28th largest by planned enrollment of the 46 interventional ones that give a count, is one of 2 that started in 2027, is one of 3 in phase 1, and was the 55th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

8 of the 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development, or all of them as a file.
02

Study summary

The COGNI-REHAB Trial is a single-site, phase O/I, randomized, double-blind, placebo-controlled study of human chorionic gonadotropin (hCG; choriogonadotropin alfa, Ovidrel®) in men with post-acute, moderate to severe traumatic brain injury (msTBI). Its objective is to assess the safety and efficacy of a 24-week regimen of Ovidrel (125 micrograms twice weekly) compared to placebo on treatment-emergent adverse events (TEAEs), cognitive and functional recovery, and circulating sex hormones.

Read the detailed description

This project aims to re-purpose a safe, well-tolerated, already-approved medication: human chorionic gonadotropin (hCG; choriogonadotropin alfa, Ovidrel®) for use in the post-acute rehabilitation of moderate to severe traumatic brain injury (msTBI). Ovidrel is currently FDA-approved for use in ovulation induction and Assisted Reproductive Technologies (ART). The rationale for using Ovidrel comes from a convergence of evidence indicating that hCG has neurodevelopmental and neuroregenerative properties, and from preclinical studies demonstrating that hCG reverses TBI-induced suppression of sex hormone production (i.e., reverses hypogonadism) and improves recovery of sensorimotor and spatial learning and memory in rodents following a focal injury to the medial prefrontal cortex. Recovery from a TBI is typically a very slow process because innate neuronal regeneration is a slow process; thus, Ovidrel (125 µg twice weekly) treatment will be evaluated over 24-weeks in patients that are 1-6 months post-TBI.

03

Conditions studied

  • Traumatic Brain Injury

Keywords

  • Traumatic brain injury
  • Human chorionic gonadotropin
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is 1-month but \< 6-month post-traumatic brain injury (TBI) with a moderate to severe traumatic brain injury (msTBI) defined as Glasgow Coma Scale (GCS) 4-12 (inclusive) at the time of the traumatic brain injury (TBI), and/or at the time of screening (Visit 1)
  • Stable doses of any medication, supplement or medical food that may affect brain function, unless deemed medically necessary by the patient's physician for optimal healthcare
  • Fluent in English
  • Reasonable expectation of availability to receive the 24-week course of therapy and be available for follow up evaluations

Exclusion criteria

Exclusion Criteria:

  • Significantly depressed (Geriatric Depression Scale > 10)
  • Patients considered to be at risk for suicidality or homicidality according to the Columbia Suicide Severity Rating Scale (CSSRS)
  • Primary hypogonadism (unrelated to trauma)
  • Renal disease; Asthma; known endocrine or germ cell tumor
  • Taking other medications known to affect serum sex hormone or gonadotropin concentrations such as testosterone for hormone replacement therapy, goserelin or danazol, in the past three (3) months
  • Presence of significant systemic illness likely to interfere with participation in or completion of the study or to affect study results
  • Receiving other drugs within 30 d or 5 half-lives prior to randomization, whichever longer
  • Male patients with known/documented elevated PSA levels, or a PSA level of 4ng/mL at screening
  • History of deep venous thrombosis (DVT) or venous thromboembolism (VTE)
  • peripheral edema
  • History of sleep apnea
  • Severe symptoms of benign prostatic hyperplasia (BPH), i.e., International Prostate Symptom Score greater than or equal to 20 points
  • Patients with known hypercoagulability, including cardiolipin/antiphospholipid antibody syndrome
  • Allergy or other to human chorionic gonadotropin (hCG)
  • Uncontrolled hypertension, defined as blood pressure persistently above 140 mm Hg systolic or 95 mm Hg diastolic despite antihypertensive therapy
  • Uncontrolled thyroid, adrenal or pituitary dysfunction
  • An uncontrolled organic intracranial lesion such as a pituitary tumor
  • History of breast or prostate cancer; sex hormone dependent tumors of the reproductive organs or accessory sex glands
  • Taking human chorionic gonadotropin (hCG), or any condition known to elevate human chorionic gonadotropin (hCG), active in the prior 24 months, e.g., choriocarcinoma or germ cell tumor
  • Patients who have 6 or more symptoms for substance use disorder according to criteria
  • Patients with evidence of an active or previous thrombotic event
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Treatment Arm

    Ovidrel: 125 micrograms in 0.25 milliliters (mL) administered subcutaneously twice weekly for 24 weeks

    Drug: Ovidrel

  • Placebo comparator
    Placebo Arm

    Placebo: 0.25 milliliters (mL) of sterile normal saline administered subcutaneously twice weekly for 24 weeks

    Other: Placebo

Interventions

  • Ovidrel, recombinant human chorionic gonadotropin, comes in a prefilled syringe for subcutaneous injection, is the investigational agent that will be used in this trial. Ovidrel® PreFilled Syringe is a sterile, liquid intended for subcutaneous (s.c.) injection. Each Ovidrel® PreFilled Syringe is filled with 0.515 milliliters (mL) containing 257.5 micrograms of choriogonadotropin alfa, 28.1 milligrams (mg) mannitol, 505 grams (g) 85% O-phosphoric acid, 103 grams (g) L-methionine, 51.5 g Poloxamer 188, Sodium Hydroxide (for pH adjustment), and Water for Injection to deliver 125 micrograms of choriogonadotropin alfa in 0.25 milliliters (mL) twice weekly. The pH of the solution is 6.5 to 7.5.

    Also known as: Choriogonadotropin alfa

  • OtherPlacebo

    Prefilled syringe of 0.250 milliliters (mL) normal saline.

06

What researchers measure

Primary outcomes

  1. Percent change in Treatment-Emergent Adverse Events

    The frequency and type of individual TEAEs, discontinuations due to TEAEs, serious TEAEs, and clinically significant changes in laboratory test values.

    Time frame: Baseline, 26 Weeks

Secondary outcomes

  1. Percent change in modified Functional Independence Measure (FIM)

    The FIM is a standardized rating of motor and cognitive disability is commonly used to guide and track progress during rehabilitation, drilling down into level of assistance required for various daily tasks.

    Time frame: Baseline, 24 Weeks

  2. Glasgow Outcome Scale-Extended (GOSE)

    The GOSE is a brief standardized tool developed for assessing TBI severity and recovery, offering a useful global indicator of disability severity.

    Time frame: Baseline, 24 Weeks

  3. Percent Change in Neuropsychiatric Inventory (NPI)

    The NPI measures psychopathology in patients with neurological disorders, this tool allows brief screening of different conditions. When a screening item is positive, it follows up with more detail of symptom types, frequency, severity, and how distressing it is to caregivers. This makes for a very efficient and useful tool, providing a more comprehensive assessment of symptoms when they are present, and can be used to track recovery.

    Time frame: Baseline, 24 Weeks

  4. Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)

    This standardized self-rated scale detects presence and severity of PTSD symptoms and is used for monitoring during recovery. This is widely used in the veteran TBI literature as PTSD is frequently comorbid with TBI and can complicate recovery. This is a necessary complement to the NPI, which doesn't assess PTSD.

    Time frame: Baseline, 24 Weeks

  5. Percent change in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

    RBANS is used in msTBI to assess cognitive impairment and track recovery in rehabilitation, this performance-based test generates a Total cognition score, which is made up of indices of Attention, Learning, Memory, Language, and Visuospatial skills. Each index can be broken down into two or more different aspects of the given cognitive domain. This allows for both global and more fine-grained analysis of cognitive impairment and recovery.

    Time frame: Baseline, 24 Weeks

  6. Percent change in Automated Neuropsychological Assessment Metrics Military (ANAM)

    ANAM is used by the US military to assess cognitive function in service members for pre-deployment screening, post-injury monitoring, TBI detection and recovery. This test complements the RBANS by offering a measure of reaction time and more robust assessment of processing speed and executive functions.

    Time frame: Baseline, 24 Weeks

  7. Percent change in Trail Making Test (TMT)

    TMT is a test of simple psychomotor speed and complex attention / executive control. It requires less manual dexterity than the RBANS and is less complicated by reaction time than the ANAM, so is useful in a mixed msTBI population as some participants may also have motor disability.

    Time frame: Baseline, 24 Weeks

  8. Columbia-Suicide Severity Rating Scale (C-SSRS)

    The "Columbia Protocol" is a brief tool used by healthcare professionals to identify if a person is at risk for suicide.

    Time frame: Baseline, 26 Weeks

Other outcomes

  1. Change in Circulating Sex Hormone Concentrations

    Percent change in circulating sex hormone concentrations.

    Time frame: Baseline, 26 Weeks

07

Study locations

1 site
08

References and documents

Publications

  • Geddes RI, Kapoor A, Hayashi K, Rauh R, Wehber M, Bongers Q, Jansen AD, Anderson IM, Farquhar G, Vadakkadath-Meethal S, Ziegler TE, Atwood CS. Hypogonadism induced by surgical stress and brain trauma is reversed by human chorionic gonadotropin in male rats: A potential therapy for surgical and TBI-induced hypogonadism? Endocrinol Diabetes Metab. 2021 Mar 18;4(3):e00239. doi: 10.1002/edm2.239. eCollection 2021 Jul. PubMed 34277964 ↗

Individual participant data

Plan to share: Yes — The data and resources sharing plan for this project is in accordance with the Veterans Administration Data Sharing Policies. All raw clinical, genetic, and imaging data from this project will be available upon written request. Deidentified data may be uploaded to one or more of several available data sharing sites designed for this purpose. The final data will be available in acceptable formats such as presentations and publications. Research data and results that document and support the study aims will be available after the final results are accepted for publication. The data to be shared will be anonymized and there will be no fees or other restrictions.

Supporting information: Study protocol, Informed consent form

Time frame: Research data and results that document and support the study aims will be available after the final results are accepted for publication.

Access criteria: Approval from PI

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Oct 2029, 33 months later.

Of 27 phase 1 interventional studies under Brain Injuries, Traumatic, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 66. This study's planned 33 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start Oct 2026 → Jan 2027, primary completion Jul 2029 → Oct 2029 and completion Sep 2029 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
Apr 29, 2026
StartEst.
Jan 1, 2027was Oct 2026
Primary completionEst.
Oct 1, 2029was Jul 2029
CompletionEst.
Dec 31, 2029was Sep 2029
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Jan 1, 2027
Oct 13, 2026
Primary completion
Jul 1, 2029→Oct 1, 2029
Oct 13, 2026
Study completion
Sep 30, 2029→Dec 31, 2029
Oct 13, 2026
Eligibility
1 inclusion criterion edited, 1 removed; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • RemovedMale subjects aged 18-65
  • EditedSubject is 1-month but < 6-month post-traumatic brain injury (TBI) with a moderate to severe traumatic brain injury (msTBI) defined as Glasgow Coma Scale (GCS) 4-12 (inclusive) at the time of the traumatic brain injury (TBI), and/or at the time of screening (Visit 1)
Exclusion criteria
  • EditedAllergy or other contraindication to human chorionic gonadotropin (hCG)
  • EditedTaking human chorionic gonadotropin (hCG), or any condition known to elevate human chorionic gonadotropin (hCG), active in the prior 24 mo.months, e.g., choriocarcinoma or germ cell tumor
Oct 13, 2026
Show all 2 updates
  1. Oct 19, 2026
    Minor edits only
    + 2 other changes: identifiers and arm descriptions
  2. Oct 13, 2026
    Start date Oct 1, 2026→Jan 1, 2027
    Primary completion Jul 1, 2029→Oct 1, 2029
    Study completion Sep 30, 2029→Dec 31, 2029
    Eligibility 1 inclusion criterion edited, 1 removed; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • RemovedMale subjects aged 18-65
    • EditedSubject is 1-month but < 6-month post-traumatic brain injury (TBI) with a moderate to severe traumatic brain injury (msTBI) defined as Glasgow Coma Scale (GCS) 4-12 (inclusive) at the time of the traumatic brain injury (TBI), and/or at the time of screening (Visit 1)
    Exclusion criteria
    • EditedAllergy or other contraindication to human chorionic gonadotropin (hCG)
    • EditedTaking human chorionic gonadotropin (hCG), or any condition known to elevate human chorionic gonadotropin (hCG), active in the prior 24 mo.months, e.g., choriocarcinoma or germ cell tumor
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07557615
Responsible party
Sponsor
First posted
Apr 29, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Oct 1, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 19, 2026

Study contacts

Craig Atwood, PhD
Contact
Craig.Atwood@va.gov
(608) 280-7000 ext. 13326
Robert Kotloski, MD
Contact
robert.kotloski@va.gov
(608) 825-1901
Craig Atwood, PhD
principal investigator · William S. Middleton Memorial Veterans Hospital, Madison, WI

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ovidrel

Start the discussion